vendredi 3 avril 2020

Onco Actu du 3 avril 2020


1. BIOLOGIE



Suspect cells’ ‘neighbor’ implicated in colorectal cancer [Yale]











2.5 ETIOLOGIE - GÉNOME



Cancer Researchers Discover Novel Inherited Mutation Predisposing Children to Medulloblastoma [Genome Web]











3. PRÉVENTION



How Can We Reduce the Risk for Esophageal Cancer? [Cancer Research Catalyst]










5.1 TRAITEMENTS - PRÉ-CLINIQUE



Tailoring an anti-cancer drug for optimal tumor cell killing [University of Montreal]











Starving Pancreatic Cancer of Cysteine May Kill Tumor Cells [Columbia University]











5.12.1 IMMUNOTHÉRAPIES - PARTENARIATS



Gilead's Kite taps Teneobio to build next-gen CAR-Ts for multiple myeloma [Fierce Biotech]











J&J gives pioneering stem cell biotech its first Big Pharma deal, partnering on iPSC CAR-T and CAR-NK [EndPoints]











Kite Licenses Antibodies and Establishes Collaboration With Teneobio in Multiple Myeloma [Gilead]











5.12.5 IMMUNOTHÉRAPIES - PHARMA



Merck looks for leg up on Bristol with Keytruda's latest colorectal cancer win [Fierce Pharma]











Merck scores new advance on tumor-agnostic front as Keytruda beat chemo-based regimens in a type of colorectal cancer [EndPoints]










5.2 PHARMA



Pfizer Receives European Approval for Oncology Biosimilar, RUXIENCE™ (rituximab) [Pfizer]











6.15 LUTTE CONTRE LES CANCERS - COVID-19



Testing for COVID-19 coronavirus at the Francis Crick Institute [Cancer Research UK]











As Coronavirus Strains Hospitals, Cancer Patients Face Treatment Delays, Uncertainty [NPR]